Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 12 · above the Ichimoku cloud · RSI 44 · MACD below its signal
None of the 29 investors followed here reported a position in 1548.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 1548.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.7 | -7.1 | -8.3 | 25.3 | -0.3 | -10.6 | 47.7 | 87.6 | 32.4 | -20.6 | +187.5% | ||
| 2025 | 8.1 | 19.3 | -2.8 | -11.7 | 17.4 | 15.4 | 16.1 | 0.1 | -2.8 | -3.7 | -7.4 | -16.9 | +25.7% |
| 2024 | -34.7 | 22.1 | -8.3 | -19.7 | -14.1 | -16.8 | 49.5 | -5.0 | 17.9 | -14.6 | -9.4 | -8.5 | −50.4% |
| 2023 | 6.4 | -18.9 | -21.7 | 22.6 | -15.9 | 1.6 | 13.4 | -7.9 | 12.4 | 9.9 | -4.4 | -8.5 | −20.1% |
| 2022 | -28.6 | 25.2 | -18.6 | -9.4 | 2.0 | 22.6 | -0.2 | -10.4 | -32.6 | 15.6 | -0.4 | 25.8 | −28.0% |
| 2021 | -11.9 | 35.2 | 2.2 | 31.6 | 69.2 | 11.3 | 0.6 | 8.4 | -18.8 | 15.2 | 18.7 | -15.9 | +206.9% |
| 2020 | 1.9 | -10.1 | -22.6 | 10.2 | 22.8 | -6.2 | 5.4 | -10.8 | -15.4 | -15.3 | 3.7 | 0.9 | −36.5% |
| 2019 | 14.0 | 21.9 | 1.0 | 35.0 | -15.3 | 15.8 | -1.1 | -9.4 | -14.6 | 25.4 | 0.3 | -6.3 | +67.6% |
| 2018 | 42.4 | -17.4 | 6.8 | 6.2 | 9.9 | -25.9 | -11.5 | -12.0 | -21.8 | -9.5 | 13.7 | -22.4 | −47.1% |
| 2017 | -5.4 | 16.0 | 3.4 | -17.6 | -4.6 | 27.9 | -1.4 | 73.8 | 3.2 | 27.7 | 4.2 | 101.2 | +440.0% |
| 2016 | 4.5 | -2.9 | 2.2 | -8.8 | -3.2 | -1.7 | 5.0 | 74.4 | 0.5 | 45.2 | 26.1 | -7.7 | +180.3% |
| 2015 | — |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Shao (Weihui)Chief Executive Officer | Sale at price 4.56 per share. | 155.5K | $708.96K |
| Sep 1, 2026 | Zhu (Li)Director (Executive) | Sale at price 4.56 per share. | 1.7K | $7.92K |
| Aug 31, 2026 | Zhu (Li)Director (Executive) | Sale at price 4.58 per share. | 32.9K | $150.70K |
| Aug 19, 2026 | Zhu (Li)Director (Executive) | Sale at price 4.23 per share. | 34K | $143.86K |
| Aug 17, 2026 | Zhu (Li)Director (Executive) | Sale at price 3.33 per share. | 98.1K | $326.20K |
| Jun 7, 2026 | Zhu (Li)Director (Executive) | Sale at price 1.55 per share. | 3K | $4.68K |
| Jun 7, 2026 | Shao (Weihui)Chief Executive Officer | Sale at price 1.55 per share. | 313.6K | $485.09K |
| Jun 3, 2026 | Shao (Weihui)Chief Executive Officer | — | 628.9K | — |
| Jun 3, 2026 | Zhu (Li)Director (Executive) | — | 20K | — |
| Apr 1, 2026 | Shao (Weihui)Chief Executive Officer | — | 52.8K | — |
| Dec 30, 2025 | Meng (Jiange)Chairman of the Board | — | 80K | — |
| Dec 30, 2025 | Meng (Jiange)Chairman of the Board | Sale at price 1.59 per share. | 41.9K | $66.65K |
| Dec 30, 2025 | Pan (Jiuan)Independent Non-Executive Director | — | 5.5K | — |
| Dec 30, 2025 | Zhu (Li)Director (Executive) | — | 40K | — |
| Dec 30, 2025 | Zhu (Li)Director (Executive) | Sale at price 1.59 per share. | 13K | $20.69K |
| Dec 14, 2025 | Quelch (John Anthony)Independent Non-Executive Director | — | 6.6K | — |
| Dec 2, 2025 | Grossman (Ross Allen)Independent Non-Executive Director | Other at price 1.86 per share. | 6.5K | $12.19K |
| Nov 13, 2025 | Zhu (Li)Director (Executive) | Sale at price 2.22 per share. | 62.9K | $139.67K |
| Sep 2, 2025 | Shao (Weihui)Chief Executive Officer | — | 119.3K | — |
| Jul 8, 2025 | Meng (Jiange)Chairman of the Board | Conversion at price 0.08 per share. | 743.3K | $56.49K |
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.
Buy / hold / sell counts
No recent headlines.